Trial Profile
A Randomized, Open-Label, Single-Dose Pilot Study of Oral and i.v. CTAP101 Evaluating PK and Safety in Stage 3 and 4 CKD Subjects With Vitamin D Insufficiency and SHPT
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Calcifediol (Primary) ; Calcifediol (Primary)
- Indications Kidney disorders; Secondary hyperparathyroidism
- Focus Pharmacokinetics
- Sponsors Cytochroma
- 09 May 2016 According to an OPKO Health media release, data from this (246046) along with other three studies (246052, 238771 & 238767) supported the New Drug Application (NDA) for CTAP101 for the prevention and treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
- 24 Jun 2014 New trial record